程超教授认为CheckMate-577研究是食管癌术后辅助治疗中可改写指南的重磅研究。在CheckMate-577研究中纳武利尤单抗对食管鳞癌患者获益匪浅,其对中国以食管鳞癌为主的疾病诊疗现状具有重要参考价值。免疫治疗为食管癌治疗开拓了新的应用前景,未来...
在CheckMate-577研究中纳武利尤单抗对食管鳞癌患者获益匪浅,其对中国以食管鳞癌为主的疾病诊疗现状具有重要参考价值。免疫治疗为食管癌治疗开拓了新的应用前景,未来可期。 术后辅助治疗柳暗花明,CheckMate-577研究携手免疫治疗重磅登场 程超教授:CheckMate-577研究是食管癌术后辅助治疗领域可改写临床诊疗指南的一项重磅研究...
CheckMate 577 是一项随机、双盲、III 期研究,共纳入 794 例新辅助放化疗后有残留病灶且接受 R0 切除的 II 或 III 期食管或胃食管交界癌患者,以 2:1 比例随机接受纳武利尤单抗(240 mg/2 周,共 16 周,此后剂量为 480 mg/4 周)或...
The CheckMate 577 trial demonstrates that nivolumab adjuvant therapy improves disease-free survival in patents without a pathological complete response. However, there are still numerous clinical questions of concern that remain controversial based on the results of the subgroup a...
Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -914 clinical trial. About CheckMate -914 CheckMate -914 is a Phase 3, randomized, double-blind, placebo-controlled tria...
Bristol Myers Squibb and Exelixis thank the patients and investigators involved in the CheckMate -9ER clinical trial. About CheckMate -9ER CheckMate -9ER is an open-label, randomized, multi-national Phase 3 trial evaluating patients with previously untreated advanced or metastatic renal...
CheckMate 577 demonstrated a significant benefit with adjuvant nivolumab for those with residual disease after esophagectomy following chemoradiation, resulting in subsequent FDA approval and guideline inclusion. We analyzed adherence to this recommendation in a non-trial setting and assessed for factors ...
CheckMate 577 是一项随机、双盲、III 期研究,共纳入 794 例新辅助放化疗后有残留病灶且接受 R0 切除的 II 或 III 期食管或胃食管交界癌患者,以 2:1 比例随机接受纳武利尤单抗(240 mg/2 周,共 16 周,此后剂量为 480 mg/4 周)或安慰剂治疗,辅助治疗最多持续 1 年,主要终点为 DFS(无病生存期)。
CheckMate-648研究证实纳武利尤单抗联合化疗一线治疗能给晚期ESCC患者带来持续生存获益,而CheckMate-577研究发现纳武利尤单抗辅助治疗使局部晚期食管癌患者的中位无病生存期(DFS)翻倍(22.4个月 vs 10.4个月)[8]。凭借该研究结果,纳武利尤单抗...